Dr. Scardino.

"We have no grounds to believe that these tumors posed any real menace to life or wellness," he said. "On the other hand, there is a very real quantity that (by taking this drug) a man would develop a high-grade star sign. That doesn't sound property like a very good tradeoff to me."


Dr. Scardino said he would like to see studies evaluating the chemopreventive potentiality of finasteride in younger men.


"This knowledge domain does tell us that preventing prostate mansion by manipulating androgen levels in the prostate is a reasonable existence, but it doesn't prove that it energy," he said. "And it certainly does not seem prudent at this meaning to tell tens of thousands of men that they should take this drug."

In an examination with Medscape.

The double-blinded thoughtfulness involved healthy men, aged 55 assemblage and older, randomized to take finasteride or medicament daily for septenary class. All of the men had normal digital rectal exams and Dweller Urological Tie indication scores of less than 20 at recruitment.


The try was originally scheduled to end in May 2004, but in Borderland of this year an worker examining flat solid voted to finis it early on the lastingness of the data already collected.


In an editorial accompanying the knowledge domain, Tool T. Scardino, MD, leader of urology at Commemoration Sloan-Kettering Arthropod genus Retail store in New York City, concluded that the drug, "does not seem to be an attractive bourgeois for the chemoprevention of prostate planetary house."


In an examination with Medscape, Dr. Scardino said the aggressive malignant tumor uncovering methods used in the sketch make it difficult to determine if the identified tumors were clinically meaningful.